Patents Examined by Laura B Goodard
  • Methods of treating urothelial carcinoma
    Patent number: 9861633
    Abstract: Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: January 9, 2018
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Siraj Mahamed Ali, Matthew J. Hawryluk, Jeffrey S. Ross, Philip James Stephens
  • Methods of treating urothelial carcinoma
    Patent number: 9610288
    Abstract: Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: April 4, 2017
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Siraj Mahamed Ali, Matthew J. Hawryluk, Jeffrey S. Ross, Philip James Stephens
  • Use of protease nexin 1 inhibitors to reduce metastasis
    Patent number: 8933212
    Abstract: The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 13, 2015
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Bérengère Fayard, Denis Monard
  • Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
    Patent number: 8771694
    Abstract: A chimeric LL2 monoclonal antibody (mAb) is described in which the variable regions of the murine LL2 mAb are recombinantly joined to the human constant region domains, which retains the immunospecificity and B-cell lymphoma and leukemia cell internalization capacity of the murine LL2 (mAB), and which exhibits reduced human anti-mouse antibody production activity (HAMA). A humanized LL2 mAb is described in which the CDRs are recombinantly joined to a framework sequence of human variable regions, and subsequently linked to human constant region domains, which retains the immunospecificity and B-lymphoma and leukemia cell internalization capacities of the murine and chimeric LL2 mABs, and has the potential for exhibiting reduced HAMA. Isolated DNAs encoding the LL2 variable and CDR framework regions are described. Conjugates of chimeric and humanized chimeric LL2 antibodies with cytotoxic agents or labels find use in therapy and diagnosis of B-cell lymphomas and leukemias.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: July 8, 2014
    Assignee: Immunomedics, Inc.
    Inventors: Shui-on Leung, Hans Hansen